logo
  

Arch Resources Turns To Profit In Q2

Coal mining company Arch Resources, Inc. (ARCH) on Tuesday swung to profit in the second quarter, aided by higher revenues. The second quarter results topped the Street estimates.

The company posted second quarter net income of $27.9 million or $1.66 per share, compared to net loss of $49.3 million or $3.26 per share in the same period last year.

On average, 4 analysts polled by Thomson Reuters expected the company to post earnings of $0.81 per share in the quarter. Analysts' estimates, usually, exclude one-time items.

Arch Resources recorded adjusted EBITDA of $66.5 million, inclusive of a $8.8 million non-cash mark-to-market loss associated with its coal-hedging activities. In the year-ago quarter, the company posted negative $10.7 million adjusted EBITDA, which included a $0.1 million non-cash mark-to-market gain associated with the coal-hedging activities.

Quarterly revenues rose to $450.4 million from $319.5 million in the prior-year period, while analysts were looking for revenues of $359.4 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million... Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT